Respiratory Syncytial Virus: Protecting Older Adults at Risk for Serious Complications

To participate in this activity, please:

Each year, respiratory syncytial virus (RSV) infects up to 10% of older adults who live in congregate settings and predisposes to an increased risk for hospitalization and death, particularly in those with comorbid cardiopulmonary disease. Stefan Gravenstein, MD, MPH, compares the burden of RSV with other viral infections in older adults and emphasizes the importance of making and how to make the diagnosis. He discusses the symptomatic management, but emphasizes the importance of instituting preventive measures since there are no currently approved medications for acute or preventive treatment of RSV in older adults (as of November 30, 2021). Dr. Gravenstein also highlights several vaccines that are in late phase development to prevent RSV infection in older adults.

This program is also available as a podcast. You may download it here:


Course Credit:

1 AMA PRA Category 1 CreditTM
1 ANCC Contact Hour
1 CA-BRN Contact Hour


Opens: 2021-11-30
Closes: 2022-11-30

Target Audience:

This activity was developed for family practice physicians, primary care physicians, nurse practitioners, nurses and other healthcare professionals who care for older adults.

This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP.

    Presenting Faculty

  • Stefan Gravenstein, MD, MPH

    Professor of Medicine
    Director, Division of Geriatrics and Palliative Care
    Brown University
    Providence, Rhode Island

  • Contributing Faculty

    Angela Branche, MD

    Assistant Professor, Department of Medicine
    University of Rochester Medical Center
    Rochester, New York